Genomic and Clinical Impact of Smoking on Therapeutic Outcomes in Colorectal Cancer: A Public Databases Analysis
Oncology · 16.11.2026
DOI: 10.1159/ocl/aebag030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, online erschienen am 16.11.2026. Verfasst von Go Kobayashi und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Smoking is associated with poor prognosis and distinct molecular alterations in CRC, but its prognostic significance across different treatment-exposed populations remains unclear. We comprehensively investigated the clinicopathological, genomic, and treatment-specific prognostic significance of smoking in CRC using large public datasets.
Methods
Clinicopathological, genomic, treatment, and survival data were obtained from the MSK-CHORD 2024 and MSK-IMPACT 50K databases. Patients were classified as smokers or non-smokers. Associations between smoking history, genomic alterations, mutation clonality, and overall survival (OS) were evaluated. Independent prognostic factors were identified using multivariable Cox regression analyses.
Results
Smokers were older, more frequently male, and had poorer baseline performance status than non-smokers. Smoking was independently associated with worse OS in the overall cohort and among patients exposed to oxaliplatin-, irinotecan-, and EGFR-targeted therapies, but not among those exposed to VEGF-targeted therapy or immune checkpoint inhibitors. Genomic analyses demonstrated that BRAF mutations and FGFR1 copy number amplifications (CNAs) were significantly enriched in smokers, whereas TCF7L2 mutations were more frequent in non-smokers. Although the overall distribution of BRAF clonality categories differed significantly according to smoking status, this difference was not statistically significant among BRAF-mutant tumors.
Conclusions
Smoking history was independently associated with poor prognosis in patients with CRC including among patients exposed to oxaliplatin-, irinotecan-, and EGFR-targeted therapies. Additionally, smokers exhibited distinct genomic characteristics, including higher frequencies of BRAF mutations and FGFR1 CNAs. These findings provide new insights into the clinical and molecular characteristics associated with smoking in CRC and warrant further validation in clinically annotated cohorts.
Autor:innen und Institutionen
ORCID-Profile: Hideki Ohdan
Zitieren
APA
Kobayashi, G., Sekino, Y., Akabane, S., Yamaguchi, M., Hinata, N., Ohdan, H., & Sato, Y. (2026). Genomic and Clinical Impact of Smoking on Therapeutic Outcomes in Colorectal Cancer: A Public Databases Analysis. Oncology. https://doi.org/10.1159/ocl/aebag030
Vancouver
Kobayashi G, Sekino Y, Akabane S, Yamaguchi M, Hinata N, Ohdan H, et al. Genomic and Clinical Impact of Smoking on Therapeutic Outcomes in Colorectal Cancer: A Public Databases Analysis. Oncology. 2026. doi:10.1159/ocl/aebag030
BibTeX
@article{Kobayashi2026,
author = {Kobayashi, Go and Sekino, Yohei and Akabane, Shintaro and Yamaguchi, Mizuki and Hinata, Nobuyuki and Ohdan, Hideki and Sato, Yuichiro},
title = {Genomic and Clinical Impact of Smoking on Therapeutic Outcomes in Colorectal Cancer: A Public Databases Analysis},
journal = {Oncology},
year = {2026},
doi = {10.1159/ocl/aebag030}
}
EUVIMED